Australia Details Biosimilar Substitution Criteria
This article was originally published in PharmAsia News
Executive Summary
The Australian government is pressing ahead with plans to allow pharmacist substitution of biosimilars after the Pharmaceutical Benefits Advisory Committee (PBAC) outlined the criteria that would have to be met if substitution was to take place.